Cost-effectiveness of procalcitonin for detection of serious bacterial infections in children presenting with fever without source
<strong>Introduction<br></strong> Procalcitonin (PCT) offers better specificity than C-reactive protein (CRP) to detect SBI. However, their cost limited their use and routine application. The objective of this work is to determine the cost-effectiveness of PCT against CPR or Roches...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BioMed Central
2022
|
| _version_ | 1797110699746394112 |
|---|---|
| author | Buendia Rodriguez, JA Guerrero Patiño, D |
| author_facet | Buendia Rodriguez, JA Guerrero Patiño, D |
| author_sort | Buendia Rodriguez, JA |
| collection | OXFORD |
| description | <strong>Introduction<br></strong>
Procalcitonin (PCT) offers better specificity than C-reactive protein (CRP) to detect SBI. However, their cost limited their use and routine application. The objective of this work is to determine the cost-effectiveness of PCT against CPR or Rochester scale in infants between 1 and 3 months from the perspective of the third payer in Colombia.
<br><strong>
Methods<br></strong>
A Monte Carlo simulation was performed with a hypothetical cohort of 10,000 patients with fever without focus (FWS) between 1 to 3 months, to estimate the number of cases correctly diagnosed for each test and the associated costs with each test.
<br><strong>
Results<br></strong>
The test with the highest number of correctly diagnosed cases was PCT 79%, followed by C-reactive protein 75%, and the Rochester scale 68%. The test with the lowest cost per patient was PCT $645 (95% CI US$646-US$645) followed by C-reactive protein U$ 653 (95% CI US$655-$645) and Rochester scale US$804 (95% CI US$807-US$804). This position of dominance of PCT eliminated the need to calculate an incremental cost effectiveness ratio.
<br><strong>
Conclusions<br></strong>
PCT is the most cost-effective strategy for the detection of IBS in infants with FWS. These results should be interpreted within the clinical context of the patient and not as a single method for therapeutic decision-making. |
| first_indexed | 2024-03-07T07:59:58Z |
| format | Journal article |
| id | oxford-uuid:11c6d2c5-a9dc-4610-bde8-771fcee6487a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:59:58Z |
| publishDate | 2022 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:11c6d2c5-a9dc-4610-bde8-771fcee6487a2023-09-19T11:33:57ZCost-effectiveness of procalcitonin for detection of serious bacterial infections in children presenting with fever without sourceJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:11c6d2c5-a9dc-4610-bde8-771fcee6487aEnglishSymplectic ElementsBioMed Central2022Buendia Rodriguez, JAGuerrero Patiño, D<strong>Introduction<br></strong> Procalcitonin (PCT) offers better specificity than C-reactive protein (CRP) to detect SBI. However, their cost limited their use and routine application. The objective of this work is to determine the cost-effectiveness of PCT against CPR or Rochester scale in infants between 1 and 3 months from the perspective of the third payer in Colombia. <br><strong> Methods<br></strong> A Monte Carlo simulation was performed with a hypothetical cohort of 10,000 patients with fever without focus (FWS) between 1 to 3 months, to estimate the number of cases correctly diagnosed for each test and the associated costs with each test. <br><strong> Results<br></strong> The test with the highest number of correctly diagnosed cases was PCT 79%, followed by C-reactive protein 75%, and the Rochester scale 68%. The test with the lowest cost per patient was PCT $645 (95% CI US$646-US$645) followed by C-reactive protein U$ 653 (95% CI US$655-$645) and Rochester scale US$804 (95% CI US$807-US$804). This position of dominance of PCT eliminated the need to calculate an incremental cost effectiveness ratio. <br><strong> Conclusions<br></strong> PCT is the most cost-effective strategy for the detection of IBS in infants with FWS. These results should be interpreted within the clinical context of the patient and not as a single method for therapeutic decision-making. |
| spellingShingle | Buendia Rodriguez, JA Guerrero Patiño, D Cost-effectiveness of procalcitonin for detection of serious bacterial infections in children presenting with fever without source |
| title | Cost-effectiveness of procalcitonin for detection of serious bacterial infections in children presenting with fever without source |
| title_full | Cost-effectiveness of procalcitonin for detection of serious bacterial infections in children presenting with fever without source |
| title_fullStr | Cost-effectiveness of procalcitonin for detection of serious bacterial infections in children presenting with fever without source |
| title_full_unstemmed | Cost-effectiveness of procalcitonin for detection of serious bacterial infections in children presenting with fever without source |
| title_short | Cost-effectiveness of procalcitonin for detection of serious bacterial infections in children presenting with fever without source |
| title_sort | cost effectiveness of procalcitonin for detection of serious bacterial infections in children presenting with fever without source |
| work_keys_str_mv | AT buendiarodriguezja costeffectivenessofprocalcitoninfordetectionofseriousbacterialinfectionsinchildrenpresentingwithfeverwithoutsource AT guerreropatinod costeffectivenessofprocalcitoninfordetectionofseriousbacterialinfectionsinchildrenpresentingwithfeverwithoutsource |